GNP+ News & Statements

The Global Network of People living with HIV (GNP+) supports the United States Government’s call for a scale up of HIV prevention efforts, particularly the scale up of HIV treatment access, and the prevention of vertical transmission. GNP+ is encouraged that the US Secretary of State Hillary Clinton has made the objective of an ‘AIDS-Free generation’ a US policy priority and will help make this objective a reality.

“Having combination prevention as a policy priority is an important step,” says Dr. Kevin Moody, International Coordinator and CEO of GNP+. “However, this policy must be transformed into action. Every day we delay scaling-up prevention and treatment services, people in dire need are affected unnecessarily.”

Read more ...

The Global Network of People living with HIV (GNP+) and the LIVING2012 Partnership are proud to announce LIVING2012, the 13^th International Conference of People living with HIV.

LIVING2012 will take place in Washington DC on 19 and 20 July, 2012. LIVING2012 has been recognized as an official pre-conference to AIDS 2012, which will take place from 22 to 27 July 2012.

Read more ...

Gilead Sciences, one of the world’s largest pharmaceutical companies, becomes the first pharmaceutical company to sign an agreement with Medicines Patent Pool (MPP), one year after the MPP's formation,. The agreement with Gilead Sciences, will allow for the sharing of the intellectual property (IP) of HIV medicines including tenofovir, emtricitabine, cobicistat, and elvitegravir. The Global Network for People living with HIV (GNP+) believes that this step, while in some part should be welcomed, cannot be completely lauded due to the significant numbers of people living with HIV that will remain unable to access much-needed medicines.

Read more ...

Amsterdam, 18 July 2011 - Preliminary results from two large studies have now shown that a daily antiretroviral tablet taken by people who do not have HIV reduces their risk of contracting HIV by up to 73%. The Partners PrEP trial involved 4758 HIV-discordant couples in Kenya and Uganda. The TDF2 trial involved 1219 men and women in Botswana.

The studies looked at both tenofovir or tenofovir plus emtricitabine (Truvada) and found that each, when taken in advance by the HIV-negative partner as a pre-exposure prophylaxis (PrEP), can prevent heterosexual transmission of HIV from men to women and from women to men.

Read more ...

Amsterdam/New York – June 9, 2011 –The Global Network of People living with HIV (GNP+) welcomes the commitment of UN member states to achieve universal access to HIV treatment by 2015. Following weeks of negotiations, a new Political Declaration on HIV and AIDS will be agreed at the High Level Meeting on HIV, which is coming to a close in New York. Member states will commit to working towards 15 million people living with HIV being on antiretroviral treatment by 2015. Achieving this target will be a critical step towards ending the global AIDS epidemic.

Read more ...